Skip to main content
SpringerLink
Log in

Tumor necrosis factor (TNF) inhibition in the treatment of vasculitis

  • Chapter
Disease-modifying Therapy in Vasculitides

Part of the book series: Progress in Inflammation Research ((PIR))

  • 53 Accesses

Abstract

Insight into the central roles of cytokines in many inflammatory disorders represents one of the major medical advances of the 1990s. During the last decade, molecular biology provided not only the techniques to investigate individual cytokines in inflammation, but also successful strategies for the inhibition of these cytokines. As described below, the identification of tumor necrosis factor (TNF) as a critical cytokine in the pathophysiology of rheumatoid arthritis (RA) and Crohn’s disease has revolutionized the treatment of these diseases [1-10]. The extrapolation and rigorous testing of cytokine modulation strategies in the vasculitides have enormous potential to improve therapies for this group of disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141–147

    Article  PubMed  CAS  Google Scholar 

  2. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ et al (1999) Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 130: 478–486

    PubMed  CAS  Google Scholar 

  3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253–259

    Article  PubMed  CAS  Google Scholar 

  4. Elliott MJ, Maini RN, Feldman M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 36: 1681–1690

    Article  PubMed  CAS  Google Scholar 

  5. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tomour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110

    Article  PubMed  CAS  Google Scholar 

  6. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, BijI H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125–1127

    CAS  Google Scholar 

  7. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563

    Article  PubMed  CAS  Google Scholar 

  8. Stack W, Mann S, Roy A, Heath P, Sopwith M, Freeman J et al (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn’s disease. Lancet 349: 521–524

    Article  PubMed  CAS  Google Scholar 

  9. Targan S, Landers C, Vidrich A, Czaja A (1995) High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterol 108: 1159–1166

    Article  CAS  Google Scholar 

  10. Targan S, Hanauer S, van Deventer S, Mayer L, Present DH, Braakman T, De Woody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 337: 1029–1035

    Article  PubMed  CAS  Google Scholar 

  11. Carswell E, Old L, Kassel R, Green S, Fiore N, Williamson B (1975) An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 75: 3666–3670

    Article  Google Scholar 

  12. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A (1985) Purification of cachectin, a lipoprotein lipase-supressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 161: 984–995

    Article  PubMed  CAS  Google Scholar 

  13. Beutler B, Greenwald D, Hulmes J, Chang M, Pan YC, Mathison J, Ulevitch R, Cerami A (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316: 552–554

    Article  PubMed  CAS  Google Scholar 

  14. Kawakami M, Pekala P, Lane M, Cerami A (1982) Lipoprotein lipase suppression in 3T3–L1 cells by an endotoxin-induced mediator from exudates cells. Proc Natl Acad Sci USA 79: 912–916

    Article  PubMed  CAS  Google Scholar 

  15. Wherry J, Pennington J, Wenzel R (1993) Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 21: S436–S440

    Article  PubMed  CAS  Google Scholar 

  16. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697–1702

    Article  PubMed  CAS  Google Scholar 

  17. van der Poll T, Lowry S (1995) Tumour necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock 3: 1–12

    PubMed  Google Scholar 

  18. Agosti J, Fisher C, Opal S, Lowry S, Balk R, Sadoff J (1994) Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR). Proc 34th Annual ICAAC 34: 65

    Google Scholar 

  19. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, double-blind, multicenter clinical trial. JAMA 273: 934–941

    Article  PubMed  CAS  Google Scholar 

  20. Hotamisligil G, Amer P, Caro J, Atkinson R, Spiegelman B (1995) Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Invest 95: 2409–2415

    Article  PubMed  CAS  Google Scholar 

  21. Hotamisligil G (1999) The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 245: 621–625

    Article  PubMed  CAS  Google Scholar 

  22. Spiegelman B, Hotamisligil G (1993) Through thick and thin: wasting, obesity, and TNF alpha. Cell 73: 625–627

    Article  PubMed  CAS  Google Scholar 

  23. Bertolini D, Nedwin G, Bringman T, Smith D, Mundy G (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human necrosis factor. Nature 319: 516–518

    Article  PubMed  CAS  Google Scholar 

  24. Saklatvala J (1986) Tumour necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547–549

    Article  PubMed  CAS  Google Scholar 

  25. Dinarello C (1999) Cytokines as endogenous pyrogens. J Infect Dis 179 (Suppl 2): S294–304

    Article  PubMed  CAS  Google Scholar 

  26. Torre-Amione G, Bozkurt B, Deswal A, Mann D (1999) An overview of tumor necrosis factor alpha and the failing heart. Curr Opin Cardiol 14: 206–210

    Article  PubMed  CAS  Google Scholar 

  27. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 1717–1725

    Article  PubMed  CAS  Google Scholar 

  28. Tracey K, Vlassara H, Cerami A (1989) Cachectin/tumor necrosis factor. Lancet 1: 1126

    Google Scholar 

  29. Banner DW, D’Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Less-lauer W (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73: 341–345

    Article  Google Scholar 

  30. Beutler B, Bazzoni F (1998) TNF, apoptosis and autoimmunity: A common thread? Blood, Cells, Molecules and Disease 24: 216–230

    Article  CAS  Google Scholar 

  31. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K (1996) Activation of transcription factor NF-KB in human synovial cells in response to tumor necrosis factor a. Arthritis Rheum 39: 197–203

    Article  PubMed  CAS  Google Scholar 

  32. Pfeffer K, Matsuyama T, Kiindig TM, Wakeham A, Kishihara K, Shahinian A, Wieg-mann K, Ohashi PS, Kronke M, Mak TW (1993) Mice deficient for the SSkD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457–467

    Article  PubMed  CAS  Google Scholar 

  33. Rothe M, Wong S, Henzel W, Goeddel D (1994) A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kD tumor necrosis factor receptor. Cell 78: 681–692

    Article  PubMed  CAS  Google Scholar 

  34. Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KC, Schreiber RP, Goeddel DV, Moore MW (1994) Decreased sensitivity to tumour necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560–563

    Article  PubMed  CAS  Google Scholar 

  35. Tartaglia L, Ayres T, Wong G, Goeddel D (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74: 845–853

    Article  PubMed  CAS  Google Scholar 

  36. Ashkenazi A, Dixit V (1998) Death receptors: signaling and modulation. Science 281: 1305–1308

    Article  PubMed  CAS  Google Scholar 

  37. Jones R, Moreland L (1999) Tumor necrosis factor inhibitors for rheumatoid arthritis. Bulletin Rheum Diseases 48: 1–4

    Google Scholar 

  38. Carlos T, Harlan J (1994) Leukocyte-endothelial adhesion molecules. Blood 84: 2068–2101

    PubMed  CAS  Google Scholar 

  39. Pennica D, Nedwin J, Hayflick P, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumor necrosis factor: precursor structure, expression, and homology to lymphotoxin. Nature 312: 724–729

    Article  PubMed  CAS  Google Scholar 

  40. Wegener F (1990) Wegener’s granulomatosis: Thoughts and observations of a pathologist. Eur Arch Otorhinolaryngol 247: 133–142

    Article  PubMed  CAS  Google Scholar 

  41. Maiti A, Maki G, Johnson P (1998) TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation. Science 282: 941–943

    Article  PubMed  CAS  Google Scholar 

  42. Paleolog E, Hunt M, Elliott M, Feldmann M, Maini R, Woody J (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum 39: 1082–1091

    Article  PubMed  CAS  Google Scholar 

  43. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha M, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 39: 1077–1081

    Article  PubMed  CAS  Google Scholar 

  44. Feldmann M, Elliott M, Woody J, Maini RN (1997) Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv Immunol 64: 283–350

    Article  PubMed  CAS  Google Scholar 

  45. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727–735

    Article  PubMed  CAS  Google Scholar 

  46. Lipsky P, St. Clair W, Kavanaugh A, McCune W, Smolen J, Breedveld F, Furst D, Kalden J, Weissman M, Braakman T et al (1998) Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNF-a antibody (infliximab) in patients with active disease on methotrexate. Arthritis Rheum 41: S364

    Google Scholar 

  47. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheum 34: 334–342

    Article  CAS  Google Scholar 

  48. Podolsky D (1991) Inflammatory bowel disease. N Engl J Med 325: 928–938

    Article  PubMed  CAS  Google Scholar 

  49. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Ann Rev Immunol 10: 411–452

    Article  CAS  Google Scholar 

  50. Jacob C, McDevitt H (1988) Tumour necrosis factor-alpha in murine autoimmune “lupus” nephritis. Nature 331: 356–358

    Article  PubMed  CAS  Google Scholar 

  51. Bannworth B, Vernhes J, Schaeverbeke T, Dehais J (1995) The facts about methotrexte in rheumatoid arthritis. Rev Rheum 62: 471–473

    Google Scholar 

  52. Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor receptor- IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174: 1483–1489

    Article  PubMed  CAS  Google Scholar 

  53. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548

    PubMed  CAS  Google Scholar 

  54. Ramey D, Fries J, Singh G (1996) The Health Assesment Questionnaire 1995 — status and review. In: B Spilker (ed): Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia

    Google Scholar 

  55. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342 (11): 763–769

    Article  PubMed  CAS  Google Scholar 

  56. Mease P, Goffe B, Metz J, Vanderstoep A (1999) Enbrel (Etanercept) in patients with psoriatic arthritis and psoriasis. Arthritis Rheum 42: S377

    Google Scholar 

  57. Sander O, Rau R, vanRiel P, vandePutte L, Hasler F, Baudin M, Lüdin E, McAuliffe T, Dickinson S, Kähny M-R et al (1996) Neutralization of TNF by lenercept (TNFR55IgG1, Ro 45–2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial. Arthritis Rheum 39 (9 Suppl): S1288

    Google Scholar 

  58. Hasler F, van de Putte L, Dumont E, Kneer J, Bock J, Dickinson S, Lesslauer W, Van der Auwera P (1996) Safety and efficacy of the neutralization by lenercept (TNFR55-IgG1, Ro 45–2081) in patients with rheumatoid arthritis exposed to a single dose. Arthritis Rheum 39 (9 Suppl): S1291

    Google Scholar 

  59. Hasler F, van de Putte L, Baudin M, Lüdin E, Durrwell L, McAuliffe T, Van der Auwera P (1996) Chronic TNF neutralization (up to 1 year) by lenercept (TNFR55-IgGl, Ro 45–2081) in patients with rheumatoid arthritis: Results of an open-label extension of a double-blind single dose phase I study. Arthritis Rheum 39 (9 Suppl): S1292

    Google Scholar 

  60. Kindler V, Sappino A, Grau G, Piguet P, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731–740

    Article  PubMed  CAS  Google Scholar 

  61. Ludviksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, Fauci AS, Strober W (1998) Active Wegener’s granulomatosis is associated with HLADR’ CD4’ T cells exhibiting an unbalanced Th1-Type T cell cytokine pattern: Reversal with IL-10. J Immun 160: 3602–3609

    PubMed  CAS  Google Scholar 

  62. Deguchi Y, Shibata N, Kishimoto S (1990) Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 81: 311–314

    Article  PubMed  CAS  Google Scholar 

  63. Nassonov EL, Samsonov MY, Tilz GP, Beketova ZV, Semenkova EN, Baranov A, Wachter H, Fuchs D (1997) Serum concentrations of neopterin, soluble interleukin 2 receptor, and doluble tumor necrosis factor receptor in Wegener’s granulomatosis. J Rheum 24: 666–670

    PubMed  CAS  Google Scholar 

  64. Jonasdottir O, Bendtzen K, Skjodt H, Petersen J (1998) Elevated serum levels of soluble tumor necrosis factor receptors in Wegener’s granulomatosis. Arthritis Rheum 41: S503

    Google Scholar 

  65. Noronha I, Kruger C, Andrassy K, Ritz E, Waldherr R (1993) In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney International 43: 682–692

    CAS  Google Scholar 

  66. Falk R, Hogan S, Carey T, Jennette J, Network G (1990) Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 11: 656–663

    Google Scholar 

  67. Falk R, Terrell R, Charles L, Jennette J (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87: 4115–4119

    Article  CAS  Google Scholar 

  68. Reumaux D, Vossebeld P, Roos D, Verhoeven A (1995) Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 86: 3189–3195

    PubMed  CAS  Google Scholar 

  69. Mayet W, Meyer Zum Buschenfelde K (1993) Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 94: 440–446

    Article  PubMed  CAS  Google Scholar 

  70. Csernok E, Ernst M, Scmitt W, Bainton D, Gross W (1994) Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 98: 244–250

    Google Scholar 

  71. Ralston D, Marsh C, Lowe M, Wewers M (1997) Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. J Clin Invest 100: 1416–1424

    Article  PubMed  CAS  Google Scholar 

  72. Stone JH, Hellmann DB, Uhlfelder ML, Bedocs NM, Crook SL, Hoffman GS (2001) Etanercept in Wegener’s granulomatosis (WG): Results of an open-label trial. Arthritis Rheum 44 (5): 1149–1154

    Article  PubMed  CAS  Google Scholar 

  73. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Adu D (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 87: 671–678

    CAS  Google Scholar 

  74. INSSYS (The International Network for the Study of Systemic Vasculitides) (1999) Vasculitis Activity Score for Wegener’s granulomatosis: A report from the International Network for Study of the Systemic Vasculitides. Arthritis Rheum 42: S317

    Google Scholar 

  75. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener’s granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488–498

    PubMed  CAS  Google Scholar 

  76. Guillevin L, Cordier J-F, Lhote F, Cohen, Pascal, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40: 2187–2198

    Article  PubMed  CAS  Google Scholar 

  77. Sneller MC, Hoffmann GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS (1995) An analysis of forty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613

    Article  PubMed  CAS  Google Scholar 

  78. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S et al (1997) A metalloproteinase disintegrin that releases tumour necrosis factor-a from cells. Nature 385: 729–736

    Article  PubMed  CAS  Google Scholar 

  79. Semmler J, Wachtal H, Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-a production by human mononuclear cells. Int J Immunopharmacol 15: 409–413

    Article  PubMed  CAS  Google Scholar 

  80. Le C, Nicolson A, Morales A, Sewell K (1997) Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor a receptor gene. Arthritis Rheum 40: 1662–1669

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Johns Hopkins Vasculitis Center, 1830 E. Monument Street, Suite 7500, Baltimore, MD, 21205, USA

    John H. Stone

Authors
  1. John H. Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Immunology, University Hospital Groningen, P.O. Box 30.001, Groningen, 9700 RB, The Netherlands

    Cees G. M. Kallenberg

  2. Department of Clinical and Experimental Immunology, University Hospital Maastricht, P.O. Box 5800, Maastricht, 6202 AZ, The Netherlands

    Jan W. Cohen Tervaert

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Stone, J.H. (2001). Tumor necrosis factor (TNF) inhibition in the treatment of vasculitis. In: Kallenberg, C.G.M., Tervaert, J.W.C. (eds) Disease-modifying Therapy in Vasculitides. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8235-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8235-4_3

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9485-2

  • Online ISBN: 978-3-0348-8235-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation